Literature DB >> 19112784

European experience with the retrograde approach for the recanalisation of coronary artery chronic total occlusions. A report on behalf of the euroCTO club.

Georgios Sianos1, Peter Barlis, Carlo Di Mario, Michail I Papafaklis, Joachim Büttner, Alfredo R Galassi, Joachim Schofer, Gerald Werner, Thierry Lefevre, Yves Louvard, Patrick W Serruys, Nicolaus Reifart.   

Abstract

AIMS: Recanalisation rates of coronary chronic total occlusions (CTO) remain sub-optimal. The retrograde technique was recently introduced to improve success rates. METHODS AND
RESULTS: From February 2005 until December 2007, 175 patients were treated with this technique in seven European centres by highly experienced operators: in 84 (48%) as primary strategy, in 41 (23.5%) immediately after antegrade failure and in 50 (28.5%) as a repeat procedure after previous antegrade failure. Baseline characteristics revealed a mean age 61.4 +/- 10.8 years with 29.5% and 39% of patients having diabetes and a prior history of MI, respectively. The mean occlusion duration was 50.8 months (determined in 32% of patients). The target vessel was: LAD 21%, LCX 6.3%, RCA 71.4%. Epicardial collaterals were accessed in 20.6% and septal in 79.4% of the patients. Overall success rate was 83.4%. In 80.6% a wire crossed the collaterals and successfully delivered distal to the occlusion; success rate in this group was 91.5%. The technique implemented in the retrograde facilitated successful recanalisation was: retrograde wire/balloon crossing in 28%, CART in 34% and marker wire/"knuckle" technique in 48%. There was a great diversity between centres referring to the retrograde technique used. According to the initial strategy success rates were: primary 89.3%, immediately after antegrade failure 65.9% and repeat procedure after antegrade failure in 88%. In patients with failure to cross the collaterals success rate was 50%. Septal rupture/haematoma occurred in 6.9% of the patients, periprocedural myocardial infarction (CK-MB rise) in 4% and TIA in 0.6% and wire entrapment in 0.6%. Mean fluoroscopy time was 59.3 mn and the mean contrast used was 420.9 ml. Drug eluting stents were implanted in all successfully recanalised vessels.
CONCLUSIONS: There is great diversity amongst European centres with respect to how the retrograde strategy has been adopted and adapted. The retrograde approach was used with high degree of success and safety and can thus be regarded as a valid contributor to the armamentarium of the modern day interventional cardiologist.

Entities:  

Mesh:

Year:  2008        PMID: 19112784     DOI: 10.4244/eijv4i1a15

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  29 in total

1.  Recanalisation of coronary chronic total occlusions with new techniques including the retrograde approach via collaterals.

Authors:  A Bufe; G Haltern; W Dinh; J Wolfertz; H Schleiting; H Guelker
Journal:  Neth Heart J       Date:  2011-04       Impact factor: 2.380

2.  Right coronary artery chronic total occlusion revascularization by knuckle technique through right gastroepiploic artery graft.

Authors:  Alfredo R Galassi; Luca Costanzo; Salvatore D Tomasello; Giulio Speciale
Journal:  Clin Res Cardiol       Date:  2010-05-08       Impact factor: 5.460

3.  Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: insights from a multicenter United States registry.

Authors:  Tesfaldet T Michael; Dimitri Karmpaliotis; Emmanouil S Brilakis; Mohammed Alomar; Shuaib M Abdullah; Ben L Kirkland; Katrina L Mishoe; Nicholas Lembo; Anna Kalynych; Harold Carlson; Subhash Banerjee; Michael Luna; William Lombardi; David E Kandzari
Journal:  Catheter Cardiovasc Interv       Date:  2014-01-31       Impact factor: 2.692

4.  [Treatment strategies for chronic total occlusion: current status and outlook].

Authors:  G S Werner
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

Review 5.  Advances in the management of coronary chronic total occlusions.

Authors:  Emmanouil S Brilakis; Dimitri Karmpaliotis; Minh N Vo; Santiago Garcia; Lampros Michalis; Khaldoon Alaswad; Parag Doshi; William L Lombardi; Subhash Banerjee
Journal:  J Cardiovasc Transl Res       Date:  2014-03-15       Impact factor: 4.132

6.  Outcomes With the Use of the Retrograde Approach for Coronary Chronic Total Occlusion Interventions in a Contemporary Multicenter US Registry.

Authors:  Dimitri Karmpaliotis; Aris Karatasakis; Khaldoon Alaswad; Farouc A Jaffer; Robert W Yeh; R Michael Wyman; William L Lombardi; J Aaron Grantham; David E Kandzari; Nicholas J Lembo; Anthony Doing; Mitul Patel; John N Bahadorani; Jeffrey W Moses; Ajay J Kirtane; Manish Parikh; Ziad A Ali; Sanjog Kalra; Phuong-Khanh J Nguyen-Trong; Barbara A Danek; Judit Karacsonyi; Bavana V Rangan; Michele K Roesle; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis
Journal:  Circ Cardiovasc Interv       Date:  2016-06       Impact factor: 6.546

Review 7.  Subintimal dissection/reentry strategies in coronary chronic total occlusion interventions.

Authors:  Tesfaldet T Michael; Aristotelis C Papayannis; Subhash Banerjee; Emmanouil S Brilakis
Journal:  Circ Cardiovasc Interv       Date:  2012-10       Impact factor: 6.546

8.  Initial experience of retrograde wire approach in coronary chronic total occlusion intervention.

Authors:  Suk Hwan Chung; Moo Hyun Kim; Long Hao Yu; Jong Sung Park; Kyung Ho Kim; Dong Sung Kum; Tae Ho Park; Kwang Soo Cha; Young Dae Kim
Journal:  Korean Circ J       Date:  2009-06-30       Impact factor: 3.243

9.  Influence of chronic kidney disease on the outcome of patients with chronic total occlusion.

Authors:  Qing-Bin Zhang; Li-Ming Chen; Min Li; Yu-Qi Cui; Chuan-Yan Zhao; Lian-Qun Cui
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

10.  New Advances in Chronic Total Occlusions.

Authors:  Nikolaos Konstantinidis; Michele Pighi; Ismail Dogu Kilic; Roberta Serdoz; Georgios Sianos; Carlo Di Mario
Journal:  Interv Cardiol       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.